{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"63.6","upperLimit":"97.3","value":"89.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"45"}],"units":"Participants"}],"description":"OS is defined as the time of start of treatment to death from any cause.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients will receive 8 cycles of induction combination therapy of carfilzomib, lenalidomide, and dexamethasone (CRd). Patients achieving stable disease or better after 8 cycles of CRd will receive lenalidomide extended dosing (phase I) for 12 cycles. After 12 cycles, patients will have the option to continue extended dosing (phase II) for one additional year Carfilzomib: Cycle 1: 20 mg/m(2) intravenous (IV) infusion over 30 minutes on days 1 and 2, then 36 mg/m(2) IV on days 8, 9, 15, and 16 Cycle 2-8: 36mg/ m(2) IV infusion over 30 minutes on days 1, 2, 8, 9, 15, and 16 Lenalidomide: Cycle 1: 25 mg oral days 2-21 of 28-day cycle; Cycle 2 - 8: 25 mg oral days 1-21 of 28-day cycle; After 8 cycles of combination carfilzomib, lenalidomide, and dexamethasone (CRd), patients may continue Lenalidomide for 12 cycles; After 12 cycles of extended dosing of Lenalidomide, patients may continue Lenalidomide for one year Dexamethasone: Cycle 1: 20 mg oral or IV on days 2, 8, 9, 15, 16, 22,","id":"OG000","title":"Carfilzomib, Lenalidomide, and Dexamethasone"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"up to 6 months","title":"Overall Survival (OS) Rate","type":"SECONDARY","unitOfMeasure":"percentage of participants"}